Endpoints News 生物医药· Elizabeth Cairns·· 28 天前AI 评分33
Roche 与 Zymeworks 达成最高 8.13 亿美元交易,合作开发临床前 T 细胞接合器
Roche taps Zymeworks in up to $813M deal for preclinical T cell engager
AI 导读
罗氏(Roche)与 Zymeworks 达成一项总额最高 8.13 亿美元的交易,获得一款三特异性 T 细胞接合器的全球权益。罗氏为此支付 5500 万美元首付款。该合作目前处于临床前阶段。
正文
Another day, another Roche deal.
The Swiss pharma is teaming up with Zymeworks, paying $55 million upfront for worldwide rights to a trispecific T cell …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
来源:Endpoints News 生物医药 · endpoints.news